Literature DB >> 28284496

QRS duration and dispersion for predicting ventricular arrhythmias in early stage of acute myocardial infraction.

E Chávez-González1, A E Rodríguez Jiménez2, F L Moreno-Martínez3.   

Abstract

OBJECTIVE: To determine the relationship between QRS duration and dispersion and the occurrence of ventricular arrhythmias in early stages of acute myocardial infarction (AMI).
DESIGN: A retrospective, longitudinal descriptive study was carried out.
SETTING: Hospital General Universitario "Camilo Cienfuegos", Sancti Spíritus, Cuba. Secondary health care. PATIENTS OR PARTICIPANTS: A total of 209 patients diagnosed with ST-segment elevation AMI from January 2012 to June 2014. MAIN VARIABLES OF INTEREST: The duration and dispersion of the QT interval, corrected QT interval, and QRS complex were measured in the first electrocardiogram performed at the hospital. The presence of ventricular tachycardia/fibrillation was assessed during follow-up (length of hospital stay).
RESULTS: Arrhythmias were found in 46 patients (22%); in 25 of them (15.9%), arrhythmias originated in ventricles, and were more common in those subjects with extensive anterior wall AMI, which was responsible for 81.8% of the ventricular fibrillations and more than half (57.1%) of the ventricular tachycardias. The widest QRS complexes (77.3±13.3 vs. 71.5±6.4ms; P=.029) and their greatest dispersion (24.1±16.2 vs. 16.5±4.8ms; P=.019) were found on those leads that explore the regions affected by ischemia. The highest values of all measurements were found in extensive anterior wall AMI, with significant differences: QRS 92.3±18.8ms, QRS dispersion 37.9±23.9ms, corrected QT 518.5±72.2ms, and corrected QT interval dispersion 94.9±26.8ms. Patients with higher QRS dispersion values were more likely to have ventricular arrhythmias, with cutoff points at 23.5ms and 24.5ms for tachycardia and ventricular fibrillation, respectively.
CONCLUSIONS: Increased QRS duration and dispersion implied a greater likelihood of ventricular arrhythmias in early stages of AMI than increased duration and dispersion of the corrected QT interval.
Copyright © 2016 Elsevier España, S.L.U. y SEMICYUC. All rights reserved.

Entities:  

Keywords:  Acute coronary syndrome; Arritmias ventriculares; Dispersión del QRS; Duración del QRS; Intervalo QT; Predictores; Predictors; QRS dispersion; QRS duration; QT interval; Síndrome coronario agudo; Ventricular arrhythmias

Mesh:

Year:  2017        PMID: 28284496     DOI: 10.1016/j.medin.2016.09.008

Source DB:  PubMed          Journal:  Med Intensiva        ISSN: 0210-5691            Impact factor:   2.491


  4 in total

1.  Using QRS loop descriptors to characterize the risk of sudden cardiac death in patients with structurally normal hearts.

Authors:  Cheng-I Wu; Yenn-Jiang Lin; I-Hsin Lee; Men-Tzung Lo; Yu-Cheng Hsieh; Amelia Yun-Yu Chen; Wei-Kai Wang; Shih-Lin Chang; Li-Wei Lo; Yu-Feng Hu; Fa-Po Chung; Ta-Chuan Tuan; Tze-Fan Chao; Jo-Nan Liao; Wan-Hsin Hsieh; Ting-Yung Chang; Chin-Yu Lin; An-Ning Feng; Chorng-Kuang How; Shih-Ann Chen
Journal:  PLoS One       Date:  2022-02-16       Impact factor: 3.240

2.  Caspofungin Effects on Electrocardiogram of Mice: An Evaluation of Cardiac Safety.

Authors:  Danielle Cristiane Correa De Paula; Elaine Amaral Leite; Carolina Morais Araujo; Renata Tupinambá Branquinho; Homero Nogueira Guimarães; Andrea Grabe-Guimarães
Journal:  Cardiovasc Toxicol       Date:  2020-08-26       Impact factor: 3.231

Review 3.  Missing Link between Molecular Aspects of Ventricular Arrhythmias and QRS Complex Morphology in Left Ventricular Hypertrophy.

Authors:  Ljuba Bacharova
Journal:  Int J Mol Sci       Date:  2019-12-19       Impact factor: 5.923

4.  Intravenous metoprolol during ongoing STEMI ameliorates markers of ischemic injury: a METOCARD-CNIC trial electrocardiographic study.

Authors:  Raquel Díaz-Munoz; María José Valle-Caballero; Javier Sanchez-Gonzalez; Gonzalo Pizarro; Juan Carlos García-Rubira; Noemi Escalera; Valentin Fuster; Rodrigo Fernández-Jiménez; Borja Ibanez
Journal:  Basic Res Cardiol       Date:  2021-07-19       Impact factor: 17.165

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.